

**Washington State Pharmacy and Therapeutics Committee & Drug Utilization Review Board**  
**Meeting by Zoom Webinar**  
**Wednesday, August 14, 2024, 9 a.m. to 4 p.m.**

Agenda		
Time	Topic	Presenter
9 a.m.	<b>Welcome &amp; Introductions</b> <b>Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)</b>	Kavita Chawla, Committee Chair
	<b>DUR Utilization</b>	Ryan Taketomo, HCA Marissa Tabile, HCA
	Apple Health Policy: <b>Cytokine and CAM Policies:</b> <ul style="list-style-type: none"> <li>• 66.27.00.AA</li> <li>• 66.27.00.AB</li> <li>• 66.27.00.AC</li> <li>• 66.27.00.AD</li> <li>• 66.27.00.AE</li> <li>• 66.27.00.AF</li> <li>• 66.27.00.AG</li> <li>• 66.27.00.AH</li> <li>• 66.27.00.AI</li> <li>• 66.27.00.AJ</li> <li>• 66.27.00.AK               <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Ryan Taketomo, HCA Marissa Tabile, HCA
	<b>Break (10 mins)</b>	All
	<b>Antiparasitics</b> <ul style="list-style-type: none"> <li>• Folic Acid Antagonists               <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Marissa Tabile, HCA
	<b>Ophthalmic Agents</b> <ul style="list-style-type: none"> <li>• Ectoparasiticides               <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Marissa Tabile, HCA
	<b>Antidepressants</b> <ul style="list-style-type: none"> <li>• GABA Receptor Modulator - Neuroactive Steroid               <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Nina Huynh, Magellan
	<b>Antiparkinson Agents</b> <ul style="list-style-type: none"> <li>• Adenosine Receptor Antagonists</li> </ul>	Nina Huynh, Magellan

*\* Stakeholders will be allowed 3 minutes for comments.*

*Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

	<ul style="list-style-type: none"> <li>• Dopaminergics</li> <li>• Monoamine Oxidase Inhibitors (MAOI) <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	
	<b>Lunch (30 mins)</b>	All
	<b>Gastrointestinal Agents</b> <ul style="list-style-type: none"> <li>• Ileal Bile Acid Transporter Inhibitors <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Nina Huynh, Magellan
	<b>Glaucoma Agents</b> <ul style="list-style-type: none"> <li>• Adrenergic Agents</li> <li>• Adrenergic Agents Combinations</li> <li>• Beta – Blockers</li> <li>• Beta - Blockers Combinations</li> <li>• Carbonic Anhydrase Inhibitors</li> <li>• Kinase Inhibitors</li> <li>• Miotics</li> <li>• Prostaglandins <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Nina Huynh, Magellan
	<b>Hematological Agents - Misc</b> <ul style="list-style-type: none"> <li>• Compliment Inhibitors - Injectable <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Nina Huynh, Magellan
	<b>Oncology Agents</b> <ul style="list-style-type: none"> <li>• Antineoplastics Combinations - Oral <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Nina Huynh, Magellan
	<b>Gastrointestinal Agents</b> <ul style="list-style-type: none"> <li>• Short Bowel Syndrome <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Marissa Tabile, HCA
	<b>Hematological Agents - Misc</b> <ul style="list-style-type: none"> <li>• Aminolevulinate Synthase 1-Directed SIRNA <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Marissa Tabile, HCA
	<b>Hematological Agents</b> <ul style="list-style-type: none"> <li>• Pyruvate Kinase Activators <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Marissa Tabile, HCA
	<b>Break (10 mins)</b>	All
	<b>Hematological Agents</b> <ul style="list-style-type: none"> <li>• Other <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Marissa Tabile, HCA
	<b>Neuromuscular Agents</b> <ul style="list-style-type: none"> <li>• Antimyasthenic/Cholinergic Agents <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> </ul> </li> </ul>	Marissa Tabile, HCA

*\* Stakeholders will be allowed 3 minutes for comments.*

*Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

	<ul style="list-style-type: none"> <li>○ Motion</li> </ul>	
	<b>Ophthalmic Agents</b> <ul style="list-style-type: none"> <li>● Nerve Growth Factors <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Marissa Tabile, HCA
	<b>Vasopressors</b> <ul style="list-style-type: none"> <li>● Misc - Oral <ul style="list-style-type: none"> <li>○ Stakeholder input*</li> <li>○ Motion</li> </ul> </li> </ul>	Marissa Tabile, HCA
	<b>Allergy</b> <ul style="list-style-type: none"> <li>● Allergenic Extracts / Biologicals – Oral</li> </ul> <b>Asthma and COPD Agents</b> <ul style="list-style-type: none"> <li>● Anticholinergics</li> <li>● Inhaled Corticosteroid Combinations</li> <li>● Inhaled Corticosteroids</li> <li>● Long Acting Muscarinic Agent / Long Acting Beta Agonist Combinations</li> <li>● Long Acting Muscarinic Agents</li> <li>● Phosphodiesterase 4 Inhibitors</li> </ul> <b>Atopic Dermatitis Agents</b> <ul style="list-style-type: none"> <li>● Immunosuppressive Agents - Topical Combinations</li> </ul> <b>Endocrine And Metabolic Agents</b> <ul style="list-style-type: none"> <li>● GAA Deficiency Agents</li> <li>● Growth Hormone Releasing Hormones (GHRH)</li> <li>● Mucopolysaccharidosis Agents</li> <li>● Somatostatic Agents</li> <li>● Urea Cycle Disorder Agents – Oral</li> <li>● Vasopressin Receptor Antagonists - Oral</li> </ul> <b>Hematopoietic Agents</b> <ul style="list-style-type: none"> <li>● Erythroid Maturation Agents</li> <li>● Erythropoiesis-Stimulating Agents (ESAS)</li> <li>● Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors</li> </ul> <b>Neuromuscular Agents</b> <ul style="list-style-type: none"> <li>● Systemic Lupus Erythematosus Agents</li> </ul> <b>Oncology Agents</b> <ul style="list-style-type: none"> <li>● Androgen Biosynthesis Inhibitors - Oral</li> <li>● Antiandrogens – Oral</li> <li>● Antiestrogens – Oral</li> <li>● Cyclin Dependent Kinases (CDK) Inhibitors – Oral</li> <li>● Hedgehog Pathway Inhibitors – Oral</li> <li>● Imidazotetrazines – Oral</li> <li>● Methyltransferase Inhibitors</li> <li>● MTOR Kinase Inhibitors – Oral</li> <li>● Retinoids – Oral</li> <li>● Topoisomerase Inhibitors – Oral</li> </ul> <b>Respiratory Agents</b> <ul style="list-style-type: none"> <li>● Pulmonary Fibrosing Agents</li> </ul> <b>Smoking Deterrents</b> <ul style="list-style-type: none"> <li>● Misc – Other</li> </ul> <b>All classes in this section:</b>	Marissa Tabile, HCA

*\* Stakeholders will be allowed 3 minutes for comments.*

*Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.

	<ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	
4:00 p.m.	<b>Drug Utilization Review (DUR) Board Adjourns</b>	Kavita Chawla, Committee Chair

For all Apple Health (Medicaid) questions:

1. Go to [HCA Support](#).
2. Click **Public**. You will need a SecureAccess Washington (SAW) account. ([View instructions for accessing SAW.](#))
3. Once you have logged into SAW, you will see the HCA Support portal.
4. Click **Make a Request**.
5. Click the **Apple Health Pharmacy** tile. This will take you to the online form.



*\* Stakeholders will be allowed 3 minutes for comments.  
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Nonye Connor at 360-725-2044.